Fulvestrant in combination with everolimus extended PFS significantly longer than fulvestrant with vistusertib or fulvestrant alone among women with hormone receptor-positive metastatic breast cancer, according to results of the randomized phase 2 MANTA trial published in JAMA Oncology.
